Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 22, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”) of the Russian Federation. The dossier was submitted in December 2015 by Pharmstandard Group, the largest Russian pharmaceutical group (“Pharmstandard”).

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 2, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 9:00 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City. A live webcast of AVEO’s presentation can

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 6, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay

Download PDF EUSA to Submit Marketing Authorization Application for Tivozanib in Advanced RCC in Q1 2016 AVEO to Host Conference Call Today, December 21, 2015 at 9:00 AM ET CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Dec. 21, 2015– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2015– AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a Director of the Company’s board of directors, effective November 6, 2015, to pursue interests outside the Company. Henri A. Termeer, Lead Outside Director of AVEO, has assumed Board leadership responsibilities. “Tuan

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 9, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update. “We completed partnerships for two of AVEO’s lead programs in the third quarter in addition to making progress toward our proposed plans to submit a European Marketing Authorization Application (MAA) for tivozanib

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 17, 2015– AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”). Under the terms of the agreement, AVEO will receive

Download PDF Company to Host Midyear Update Conference Call Today, August 10 at 10:00 am ET CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 10, 2015– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015. “The second quarter was productive on multiple fronts for AVEO, including clinical updates, regulatory guidance and another partnership for tivozanib, in addition to completion of our